Market Overview

The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Share:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs
Related IBB
The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns
The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait
Related PFE
Goldman Drops Alnylam From Conviction List, But Continues To See 'Blockbuster Potential'
The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings
Sangamo Therapeutics: More Catalysts Powering A Gene-Based Innovator (Seeking Alpha)

Biotech stocks saw modest gains this week, with earnings providing a boost even as clinical trial results elicited a mixed reaction.

Eli Lilly And Co (NYSE: LLY), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Gilead Sciences, Inc. (NASDAQ: GILD) are among some prominent biotechs that reported solid results and offered optimistic assessments for thenear-to-medium term. 

Looking ahead to the upcoming week, biotech investors should watch for the following catalytic events. 

Conferences

  • Global Experts Meeting On Diabetes, Hypertension & Metabolic Syndrome: July 30-31 in Melbourne, Australia.
  • 8th International Conference on Geriatrics Gerontology & Palliative Nursing: July 30-31 in Barcelona, Spain.
  • International Pan Pacific Conference of ART & Perinatology: Aug. 3-5 in Las Vegas.

PDUFA Dates

FDA is set to announce its verdict on Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX)'s rare neuroendocrine tumor treatment candidate Azedra on Sunday, July 30.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and AbbVie Inc (NYSE: ABBV) await the FDA's ruling on Elagolix for endometriosis-associated pain. Based on the three-month extension in the review period announced by the FDA on April 10, the decision could come in July or early August.

See Also: Tricida Post-IPO Run-up Makes Goldman Wary

Earnings

Monday

  • Tandem Diabetes Care Inc (NASDAQ: TNDM) (after the close)
  • GenMark Diagnostics, Inc (NASDAQ: GNMK) (after the close)
  • Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) (before the open)

Tuesday

  • Pulse Biosciences Inc (NASDAQ: PLSE) (after the close)
  • Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (after the close)
  • NewLink Genetics Corp (NASDAQ: NLNK) (after the close)
  • Incyte Corporation (NASDAQ: INCY) (before the open)
  • Medpace Holdings Inc (NASDAQ: MEDP) (before the open)
  • Hologic, Inc. (NASDAQ: HOLX) (after the close)
  • Pfizer Inc. (NYSE: PFE) (before the open)
  • NuVasive, Inc. (NASDAQ: NUVA) (after the close)
  • Qiagen NV (NYSE: QGEN)
  • Illumina, Inc. (NASDAQ: ILMN) (after the close)

Wednesday

  • Conatus Pharmaceuticals Inc (NASDAQ: CNAT) (after the close)
  • Amarin Corporation plc (ADR) (NASDAQ: AMRN) (before the open)
  • ArQule, Inc. (NASDAQ: ARQL) (before the open)
  • AtriCure Inc. (NASDAQ: ATRC) (after the close)
  • AxoGen, Inc (NASDAQ: AXGN)
  • Blueprint Medicines Corp (NASDAQ: BPMC) (before the open)
  • EXACT Sciences Corporation (NASDAQ: EXAS) (after the close)
  • Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) (after the close)
  • Globus Medical Inc (NYSE: GMED) (after the close)
  • IDEXX Laboratories, Inc. (NASDAQ: IDXX) (before the open)
  • Clovis Oncology Inc (NASDAQ: CLVS) (after the close)
  • DURECT Corporation (NASDAQ: DRRX) (after the close)
  • Exelixis, Inc. (NASDAQ: EXEL) (after the close)

Thursday

  • Genomic Health, Inc. (NASDAQ: GHDX) (after the close)
  • Obalon Therapeutics Inc (NASDAQ: OBLN) (before the open)
  • Acceleron Pharma Inc (NASDAQ: XLRN) (after the close)
  • Insmed Incorporated (NASDAQ: INSM) (before the open)
  • Seres Therapeutics Inc (NASDAQ: MCRB) (before the open)
  • Curis, Inc. (NASDAQ: CRIS) (before the open)
  • Acorda Therapeutics Inc (NASDAQ: ACOR) (before the open)
  • AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) (after the close)
  • Agios Pharmaceuticals Inc (NASDAQ: AGIO) (before the open)
  • Becton Dickinson and Co (NYSE: BDX) (before the open)
  • Arbutus Biopharma Corp (NASDAQ: ABUS) (after the close)
  • Emergent Biosolutions Inc (NYSE: EBS) (after the close)
  • T2 Biosystems Inc (NASDAQ: TTOO) (after the close)
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (after the close)
  • Pacific Biosciences of California (NASDAQ: PACB) (after the close)
  • Nevro Corp (NYSE: NVRO) (after the close)
  • Cerus Corporation (NASDAQ: CERS) (after the close)
  • TESARO Inc (NASDAQ: TSRO) (after the close)
  • Regeneron Pharmaceuticals Inc (NASDAQ: REGN) (before the open)
  • Revance Therapeutics Inc (NASDAQ: RVNC) (after the close)
  • Pacira Pharmaceuticals Inc (NASDAQ: PCRX) (before the open)
  • Zoetis Inc (NYSE: ZTS) (before the open)
  • ResMed Inc. (NYSE: RMD)
  • Insulet Corporation (NASDAQ: PODD) (after the close)
  • Glaukos Corp (NYSE: GKOS) (after the close)
  • Repligen Corporation (NASDAQ: RGEN) (before the open)
  • Epizyme Inc (NASDAQ: EPZM) (before the open)
  • Aratana Therapeutics Inc (NASDAQ: PETX)

IPO

Bionano Genomics, an instrumentation company operating in the genome analysis space, is proposing to offer 3.35 million shares in an IPO, with the price range estimated between $8 and $10. The company intends to list its shares on the Nasdaq under the ticker symbol "BNGO."

Posted-In: Biotech Earnings News Health Care Previews FDA Top Stories Trading Ideas Best of Benzinga

 

Related Articles (ABBV + ABUS)

View Comments and Join the Discussion!

SEC Rule On Direxion Bitcoin ETFs Expected This Fall

Not The Sweetest Of News: Necco Shuts Down Factory